The DRIP Trial
Phase 2
Completed
- Conditions
- Phlebitis and other adverse outcomes of peripheral venous cannulation.Inflammatory and Immune System - Rheumatoid arthritis
- Registration Number
- ACTRN12605000147684
- Lead Sponsor
- Joan Webster
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 754
Inclusion Criteria
1. they are inpatients at the Royal Brisbane and Women's Hospital. 2. They are scheduled or expected to have a peripheral venous catheter indwelling for at least 4 days.
Exclusion Criteria
1. Patients with an existing bloodstream infection 2. Those receiving immunosupressive treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method I/V related morbidity (using a composite measure of any reason for unplanned cannula removal)[Catheter removal]
- Secondary Outcome Measures
Name Time Method Cost[At completion of trial]